Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Latest Articles
Submit an article Journal homepage
588
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Lepodisiran, an siRNA targeting lipoprotein(a) for the potential future treatment of cardiovascular disease

P. Mihika S. Fernandoa Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western, AustraliaView further author information
,
Amanda J. Hoopera Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western, Australia;b School of Medicine, University of Western Australia, Perth, Western Australia, AustraliaView further author information
&
John R. Burnetta Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western, Australia;b School of Medicine, University of Western Australia, Perth, Western Australia, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0135-6119View further author information
ORCID Icon
Received 17 Mar 2024, Accepted 02 May 2024, Published online: 08 May 2024

References

  • Marcovina SM. Lipoprotein(a): a genetically determined risk factor for cardiovascular disease. Crit Rev Clin Lab Sci. 2023 Dec;60(8):560–572. doi: 10.1080/10408363.2023.2229915
  • Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):465–474. doi: 10.1161/ATVBAHA.120.315291
  • Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009 Jun 10;301(22):2331–2339. doi: 10.1001/jama.2009.801
  • Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for Lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018 Jul 1;3(7):619–627. doi: 10.1001/jamacardio.2018.1470
  • Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925–3946. doi: 10.1093/eurheartj/ehac361
  • Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. New Engl J Med. 2009;361(26):2518–2528. doi: 10.1056/NEJMoa0902604
  • Chemello K, Chan DC, Lambert G, et al. Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis. 2022 May;349:82–91. doi: 10.1016/j.atherosclerosis.2022.04.002
  • Pokrovsky SN, Afanasieva OI, Ezhov MV. Therapeutic apheresis for management of Lp(a) hyperlipoproteinemia. Curr Atheroscler Rep. 2020 Sep 18;22(11):68. doi: 10.1007/s11883-020-00886-0
  • Schwartz GG, Ballantyne CM. Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis. 2022 May;349:110–122. doi: 10.1016/j.atherosclerosis.2022.04.020
  • Banach M, Penson PE. Statins and Lp(a): do not make perfect the enemy of excellent. Eur Heart J. 2020 Jan 1;41(1):190–191. doi: 10.1093/eurheartj/ehz775
  • Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020 Jan 16;382(3):244–255. doi: 10.1056/NEJMoa1905239
  • Nicholls SJ, Nissen SE, Fleming C, et al. Muvalaplin, an oral small molecule inhibitor of Lipoprotein(a) formation: a randomized clinical trial. JAMA. 2023 Sep 19;330(11):1042–1053. doi: 10.1001/jama.2023.16503
  • O’Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022 Nov 17;387(20):1855–1864. doi: 10.1056/NEJMoa2211023
  • Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting Lipoprotein(a) production in individuals with elevated plasma Lipoprotein(a) levels. JAMA. 2022 May 3;327(17):1679–1687. doi: 10.1001/jama.2022.5050
  • Nissen SE, Linnebjerg H, Shen X, et al. Lepodisiran, an extended-duration short interfering RNA targeting Lipoprotein(a): a randomized dose-ascending clinical trial. JAMA. 2023 Dec 5;330(21):2075–2083. doi: 10.1001/jama.2023.21835

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.